
|Articles|April 2, 2007
Latebreakers: Breast cancer agent gets green light
Patients with HER2-positive advanced or metastatic breast cancer whose disease has progressed following treatment with an anthracycline, a taxane, and trastuzumab (Herceptin, Genentech) will now have a new therapeutic option. Lapatinib (Tykerb, GlaxoSmithKline) has been approved by the FDA for use in combination with capecitabine (Xeloda, Roche) following a priority review.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
Embedded Pharmacists Are Vital Yet Underutilized in Diabetes Care
2
The Prodigious PBM Pivot: How Supply Chain Entities Will Move Forward After CAA 2026
3
Executive Order Calls for Realignment of Childhood Vaccines
4
Pneumococcal Vaccination at 50 Years Old Can Improve Outcomes
5





























































